highly significantp < 0.001
Even when the results of the largest study (DECLARE) was removed, the result remained highly significant ( p < 0.001).
Even when the results of the largest study (DECLARE) was removed, the result remained highly significant ( p < 0.001).
The reported events were fewer in the canagliflozin studies, and the treatment effect showed a trend towards a reduction of SAE AKIs (OR 0.72 [95% CI 0.43–1.20], p = 0.20).